JP2008525479A - トレフォイル因子およびそれを用いた増殖性疾患の処置方法 - Google Patents

トレフォイル因子およびそれを用いた増殖性疾患の処置方法 Download PDF

Info

Publication number
JP2008525479A
JP2008525479A JP2007548477A JP2007548477A JP2008525479A JP 2008525479 A JP2008525479 A JP 2008525479A JP 2007548477 A JP2007548477 A JP 2007548477A JP 2007548477 A JP2007548477 A JP 2007548477A JP 2008525479 A JP2008525479 A JP 2008525479A
Authority
JP
Japan
Prior art keywords
tff
tff3
cells
tff1
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007548477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525479A5 (https=
Inventor
ピーター イー． ロビー
Original Assignee
オークランド ユニサービシス リミテッド
ニューレン ファーマシューティカルズ リミテッド
ニューレン ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004907226A external-priority patent/AU2004907226A0/en
Application filed by オークランド ユニサービシス リミテッド, ニューレン ファーマシューティカルズ リミテッド, ニューレン ファーマシューティカルズ インコーポレーティッド filed Critical オークランド ユニサービシス リミテッド
Publication of JP2008525479A publication Critical patent/JP2008525479A/ja
Publication of JP2008525479A5 publication Critical patent/JP2008525479A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
JP2007548477A 2004-12-22 2005-12-22 トレフォイル因子およびそれを用いた増殖性疾患の処置方法 Pending JP2008525479A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2004907226A AU2004907226A0 (en) 2004-12-22 TFF3 antagonists
AU2004907263A AU2004907263A0 (en) 2004-12-22 Methods of treatment
AU2004907262A AU2004907262A0 (en) 2004-12-22 Methods of treatment
PCT/US2005/046634 WO2006069253A2 (en) 2004-12-22 2005-12-22 Trefoil factors and methods of treating proliferation disorders using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013251639A Division JP2014088393A (ja) 2004-12-22 2013-12-05 トレフォイル因子およびそれを用いた増殖性疾患の処置方法

Publications (2)

Publication Number Publication Date
JP2008525479A true JP2008525479A (ja) 2008-07-17
JP2008525479A5 JP2008525479A5 (https=) 2009-02-12

Family

ID=36602332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007548477A Pending JP2008525479A (ja) 2004-12-22 2005-12-22 トレフォイル因子およびそれを用いた増殖性疾患の処置方法
JP2013251639A Pending JP2014088393A (ja) 2004-12-22 2013-12-05 トレフォイル因子およびそれを用いた増殖性疾患の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013251639A Pending JP2014088393A (ja) 2004-12-22 2013-12-05 トレフォイル因子およびそれを用いた増殖性疾患の処置方法

Country Status (5)

Country Link
US (2) US20090022708A1 (https=)
EP (1) EP1833991A4 (https=)
JP (2) JP2008525479A (https=)
NZ (1) NZ556158A (https=)
WO (1) WO2006069253A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517500A (ja) * 2012-05-09 2015-06-22 ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用
KR20210008914A (ko) * 2014-01-24 2021-01-25 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
WO2021108511A1 (en) * 2019-11-26 2021-06-03 Alkahest, Inc. Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743476A (zh) * 2006-10-03 2010-06-16 尼瑞医药品有限公司 结合三叶因子的构象特异性抗体以及使用该抗体治疗癌症以及增殖疾病的方法
US20090304700A1 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals, Ltd. Conformation specific antibodies that bind trefoil factors
WO2011068865A1 (en) * 2009-12-01 2011-06-09 Board Of Trustees Of Southern Illinois University Micro-rna-101 promotes estrogen-independent growth and confers tamoxifen resistance in er-positive cancer cells
CN103096917A (zh) 2010-06-04 2013-05-08 三叶草私人有限公司 用于治疗慢性肺病的三叶因子（tff）
WO2012038825A2 (en) * 2010-09-21 2012-03-29 Auckland Uniservices Limited Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1)
WO2012150869A1 (en) * 2011-05-05 2012-11-08 Neuren Pharmaceuticals Limited Antibodies that bind trefoil factors and methods of using same
CA3053267A1 (en) * 2017-02-10 2018-08-16 Vivibaba, Inc Compositions and methods for recombinant nerve growth factor
AU2020338947A1 (en) * 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
AU2022274703A1 (en) * 2021-05-12 2023-08-17 Alkahest, Inc. Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators
CN113721019A (zh) * 2021-09-05 2021-11-30 苏州银湾细胞生物科技有限公司 胆管癌术后生存预测方法、试剂盒以及试剂盒的应用方法
CN116286995A (zh) * 2023-03-24 2023-06-23 清华大学深圳国际研究生院 一种多西霉素浓度梯度依赖性tff3诱导表达质粒及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051628A2 (en) * 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2002516062A (ja) * 1997-12-23 2002-06-04 ザ カーネギー インスチチューション オブ ワシントン 二本鎖ｒｎａによる遺伝子阻害
WO2004039961A2 (en) * 2002-10-31 2004-05-13 The Gi Company, Inc. Trefoil domain-containing polypeptides and uses thereof
JP2004534075A (ja) * 2001-06-14 2004-11-11 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆｆダイマーペプチドによる粘膜修復
JP2004534801A (ja) * 2001-06-14 2004-11-18 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆｆ２ペプチドによる粘膜修復
WO2005042010A1 (en) * 2003-10-30 2005-05-12 Novo Nordisk A/S Use of trefoil polypeptides in the treatment of diabetes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US650559A (en) * 1900-01-31 1900-05-29 American Type Founders Co Gas-burner.
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
CA2103064A1 (en) 1991-05-14 1992-11-15 George Y. Wu Targeted delivery of genes encoding immunogenic proteins
DK0587738T3 (da) 1991-06-05 2000-12-18 Univ Connecticut Destineret levering af gener, som koder for sekretionsproteiner
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030125265A1 (en) * 2001-05-09 2003-07-03 Mien-Chie Hung Anti-estrogen receptor agents for chemotherapy
US20030193682A1 (en) * 2002-04-10 2003-10-16 Parry Travis J. Method and system for partitioning multiple media handling jobs
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030215431A1 (en) * 2002-02-11 2003-11-20 Lars Thim Management of mucosal viscosity by TFF monomer peptides
DE10215320A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Verwendungen von TFF3 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2004263140A1 (en) * 2003-08-07 2005-02-17 Novartis Vaccines And Diagnostics, Inc. Trefoil factor 3 (TFF3) as a target for anti-cancer therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516062A (ja) * 1997-12-23 2002-06-04 ザ カーネギー インスチチューション オブ ワシントン 二本鎖ｒｎａによる遺伝子阻害
WO2001051628A2 (en) * 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2004534075A (ja) * 2001-06-14 2004-11-11 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆｆダイマーペプチドによる粘膜修復
JP2004534801A (ja) * 2001-06-14 2004-11-18 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆｆ２ペプチドによる粘膜修復
WO2004039961A2 (en) * 2002-10-31 2004-05-13 The Gi Company, Inc. Trefoil domain-containing polypeptides and uses thereof
WO2005042010A1 (en) * 2003-10-30 2005-05-12 Novo Nordisk A/S Use of trefoil polypeptides in the treatment of diabetes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6011047107; Ｆｏｏｄ　Ａｄｄｉｔ　Ｃｏｎｔａｍ．，　２１［２］　（２００４．０２）　ｐ．１３４-１４４ *
JPN6011047110; ＧＩ　Ｒｅｓ．，　１０［３］　（２００２）　ｐ．２１１-２１７ *
JPN6011047113; ＦＥＢＳ　Ｌｅｔｔ．，　４０８　（１９９７）　ｐ．１２１-１２３ *
JPN6011047115; ＢＢＡ．，　１５７８　（２００２）　ｐ．１２-２０ *
JPN6011047118; 細胞，　３２［８］　（２０００）　ｐ．２４-２７ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517500A (ja) * 2012-05-09 2015-06-22 ザ ホン コン ユニバーシティ オブ サイエンス アンド テクノロジイ Ｍｃｍ複合体を阻害するための方法および化合物ならびにガン処置におけるそれらの適用
US11648258B2 (en) 2012-05-09 2023-05-16 The Hong Kong University Of Science And Technology Method and compounds for inhibiting the MCM complex and their application in cancer treatment
KR20210008914A (ko) * 2014-01-24 2021-01-25 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR102291465B1 (ko) 2014-01-24 2021-08-18 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
WO2021108511A1 (en) * 2019-11-26 2021-06-03 Alkahest, Inc. Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators

Also Published As

Publication number Publication date
WO2006069253A2 (en) 2006-06-29
US20090022708A1 (en) 2009-01-22
US20100129370A1 (en) 2010-05-27
JP2014088393A (ja) 2014-05-15
EP1833991A2 (en) 2007-09-19
EP1833991A4 (en) 2011-11-16
NZ556158A (en) 2010-04-30
WO2006069253A3 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
JP2014088393A (ja) トレフォイル因子およびそれを用いた増殖性疾患の処置方法
JP5857056B2 (ja) 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
CN107709359A (zh) Ror1‑ror2结合的调节剂
US20100203060A1 (en) Inhibitors for growth hormone and related hormones, and methods of use thereof
US20110124564A1 (en) Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same
EP2164870A1 (en) Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
AU2012267492A1 (en) Modulation of pancreatic beta cell proliferation
CN103690928A (zh) 新型癌抗原eEF2
EP3108257B1 (en) Methods and uses of mitofusins
WO2011054644A1 (en) A low density lipoprotein-related protein 1 splice variant as cancer marker
US10195166B2 (en) Methods for treating hepatitis C virus infectious disease
US20070298445A1 (en) Cancer Therapeutic
TWI395948B (zh) 新穎之生理物質ｎｅｓｆａｔｉｎ及其相關物質、以及此等之用途
KR101137019B1 (ko) 신규한 ｇｐｃｒ 단백질 및 이의 용도
JP2007517498A (ja) 骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用
JP5514443B2 (ja) カテコールアミン調節性タンパク質
KR101249041B1 (ko) 결합조직 성장인자를 이용한 약학적 조성물
Wang et al. Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery
AU2005319132A1 (en) Trefoil factors and methods of treating proliferation disorders using same
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
US20040242526A1 (en) Disruption of the REG pathway
WO2025199495A1 (en) Compositions and methods for treatment and prevention of alzheimer's disease
CN101161283A (zh) CMTM1-v17的新应用及其拮抗剂
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
WO2012038825A2 (en) Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131205